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ABSTRACT
TRENDS IN PERTUSSIS INCIDENCE IN GEORGIA FROM 2010 – 2020 BASED ON THE 2020
CSTE/CDC CASE DEFINITION
By
GINA URSULA RADERALAZASOA
7/20/2021

INTRODUCTION: Pertussis is a highly contagious respiratory infection transmitted from person
to person in close contact. Its burden is high among unvaccinated infants (< 1 year) due to age
appropriateness, and the number of cases has been on the rise among adolescents and adults in
the past ten years. In 2020, a change in pertussis case definition (CD) was issued by the Council
of State and Territorial Epidemiologists (CSTE), classifying PCR-positive cases as confirmed cases
regardless of cough duration. This study aims to assess whether the change in pertussis CD affects
the number of confirmed and probable pertussis cases reported in Georgia from 2010 -2020 and
evaluate its effectiveness.
METHODS: Epidemiologic data were obtained from the State Electronic Notifiable Disease
Surveillance System (SendSS). Based on the 2020 CSTE/CDC case definition, reported pertussis
cases were re-evaluated as confirmed, probable, and not-a-case (NAC). A cross-sectional study
was performed. The characteristics of all reported pertussis cases were first described. Then, the
incidence rates were compared under the old and new CDs. Last, sensitivity, specificity, predictive
value positive (PVP), and predictive value negative (PVN) of the new CD were estimated.
RESULTS: From 2010 to 2020, there were 3,882 reported pertussis cases in Georgia. About 22%
(n=867) of reported pertussis cases were among infants < 1 year. Cough duration was
inconsistent across case classification. PCR was ordered in 62.28% (n=2,176), whereas culture in
8.67% (n=303) only. More than half of the laboratory-confirmed cases were obtained from PCR.
Between 2010 and 2020, 2,765 (71.23%) reported cases were considered as pertussis cases
(confirmed and probable), and 1,117 (28.77%) were NACs, using the previous CDs issued in 2010
and 2014. After reclassification based on the 2020 CSTE/CDC case definition, 3,213 (82.77%) were

considered as cases, whereas 669 (17.23%) were NACs. Fifty-eight percent (n=137, 95% CI:
[50.79% – 65.31%] of pertussis cases would have been missed in 2020 if the 2014 CSTE/CDC case
definition was still in use. The incidence rate of pertussis cases was 1.16 times higher with the
new CD than the old CD. The new CD was estimated to have 83.80% [95%CI: 82.42 – 85.17]
sensitivity and 72.11% [95%CI: 70.56% – 73.66%] predictive value positive.
CONCLUSION: Pertussis is a remerging infectious disease that needs better control and
surveillance. Changing the clinical criteria of illness of cough ≥ 2 weeks to cough of any duration
and accounting PCR-positive cases as laboratory-confirmed cases were found to be effective in
capturing more pertussis cases in Georgia. Despite the limitations of this study, it demonstrates
the usefulness of updating case definitions with reliable diagnostic tools. These findings can be
used to reinforce the capacity of health districts and public health departments to identify
pertussis cases accurately and deploy the necessary resources. Standardized and evidence-based
tools are essential for notifiable diseases surveillance to monitor trends and stop epidemics on
time. Future research could expand on adopting an integrated approach to surveillance of
emerging infectious diseases.
KEYWORDS: Bordetella pertussis, case definition, incidence, surveillance.
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Chapter I – Introduction
Pertussis or whooping cough is a highly contagious respiratory infection caused by Bordetella
pertussis bacteria. In 2014, the World Health Organization (WHO) estimated 24.1 million
pertussis cases and 160,700 deaths occurred globally, where 21% of the cases and 53% of the
estimated deaths were found in infants less than 12 months old (Yeung et al., 2017). Symptoms
in adolescents and adults are usually mild or atypical, leading to underreported cases, but those
with mild illness can still transmit the disease to unvaccinated individuals (Sanstead et al., 2015).
Young infants are often incompletely or not vaccinated because the earliest dose of the pertussis
vaccine DTaP can be administered at 2 months of age. The five doses recommended for children
will not be complete until age 6, according to the Advisory Committee on Immunization Practices
(ACIP) recommendations (CDC, 2020b).
In 2010 and 2012, pertussis cases peaked in the United States (U.S.) with more than 27,000 cases
and 48,277 cases, respectively (CDC, 2019). About 35% of the cases were among children, mostly
under 3 months old (Syed & Bana, 2014). The risk of pertussis-related complications and death is
highest among infants < 1 year; about half of these infantile pertussis cases required
hospitalization (CDC, 2021a).
Pertussis is preventable through vaccination. Since the implementation of routine childhood
vaccination in 1940s, pertussis mortality and morbidity decreased in the U.S. (CSTE, 2019).
However, this success was short-lived as the number of reported pertussis cases has increased
during the past 40 years despite the widespread vaccination (Syed & Bana, 2014). Moreover,
immunity against pertussis does not confer life-long protection, either after natural infection or
induced by vaccination, lasting about 5 – 8 years (Chiappini et al., 2013). Thus, pertussis has been
the least controlled of all bacterial vaccine-preventable diseases in the U.S. (Masseria et al.,
2017).
In 2020, the Council of State and Territorial Epidemiologists (CSTE) issued a change in pertussis
case definition (CD), intended to capture the disease across all age groups better and precisely
estimate its burden (CSTE, 2019). According to the Centers for Disease Control and Prevention
(CDC), a surveillance CD is a set of uniform criteria to define a disease that enables public health
officials to classify and count cases consistently across reporting jurisdictions (CDC, 2021d).
1

Previously, the criteria for confirmed cases included a positive culture and the presence of cough
or a positive polymerase chain reaction (PCR) with cough onset of 14 days or more. Although
culture was considered the gold standard to diagnose pertussis, PCR is currently the most widely
used diagnostic tool for pertussis because it has become more efficient and accurate over time.
Thus, the new classification considers PCR-positive cases as confirmed, regardless of cough
duration (CSTE, 2019).
Since pertussis is reportable in Georgia, this study aims to measure how this change in CD affects
the number of confirmed and probable pertussis cases reported from 2010 -2020 and assess its
effectiveness.
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Chapter II – Literature Review
1. Epidemiology
Pertussis remains a public health issue worldwide. The first described outbreaks occurred in the
16th century (Kilgore et al., 2016). Bordetella pertussis was first isolated in 1906, and pertussis
was one of the most common childhood illnesses of the 20 th century (CDC, 2020d). It was also a
major cause of childhood mortality in the U.S., with 1 death per 10 cases, and it killed more
children annually than polio and measles combined (Clark, 2014). Countries with a large
population, such as China, India, Indonesia, Nigeria, and Pakistan, could have underreported
pertussis cases (Syed & Bana, 2014). In 1940, a whole-cell vaccine that induced an immune
response similar to a natural B. pertussis infection became available worldwide and was routinely
used for childhood immunization (Clark, 2014). As a result, pertussis incidence has decreased
more than 75% than that of the pre-vaccine era (CDC, 2020d). However, the whole-cell vaccines
had been reported to be associated with adverse reactions with increasing age and the number
of administered doses. In the 1990s, the replacement of these whole-cell vaccines with less
reactogenic acellular vaccines resulted in the resurgence of the disease among adolescents and
school-aged children (Figure 1) (Gabutti et al., 2015). Previous studies suggest that possible
reasons for this re-emergence of pertussis include increased reporting due to the increased
awareness of the disease, the development of new clinical definitions, and the widespread use
of PCR for laboratory confirmation, but also, the waning of immunity after natural infection or
vaccination (Chiappini et al., 2013). Pertussis cases in adults are often subsequent, mild, or
asymptomatic infections that remain undetected and putting unvaccinated children at risk of
transmission (Sanstead et al., 2015). Also, immunity against pertussis is transient, with outbreaks
occurring every 3 – 5 years (Gabutti et al., 2015).
In the U.S., state health departments report suspected, probable, and confirmed pertussis cases
to the CDC through the National Notifiable Diseases Surveillance System (NNDSS) (CDC, 2021b).

3

Figure 1. Reported pertussis incidence by age group in the U.S., 1990 – 2018.
Source: https://www.cdc.gov/pertussis/surv-reporting.html.
2. Pathogenesis
Pertussis, also known as whooping cough, is an airborne bacterial respiratory infection caused by
Bordetella pertussis. Other Bordetella species (B. parapertussis and B. holmesii) can cause milder
whooping cough-like symptoms in humans and can also infect animals. In contrast, B. pertussis is
specific to humans (Kilgore et al., 2016). This pathogen is an aerobic, Gram-negative bacterium.
It is virulent due to its antigenic and biologically active components such as pertussis toxin (PT),
filamentous hemagglutinin (FHA), fimbriae (FIM), pertactin (PRN), agglutinogens, adenylate
cyclase toxin (AC), dermonecrotic toxin (DNT), and tracheal cytotoxin (TC) (CDC, 2020d). B.
pertussis is transmitted from person to person through aerosol droplets. The incubation period
is typically 7 – 10 days but can range from 4 – 21 days (CDC, 2020d). The bacteria adhere to the
cilia of the tracheal epithelium and lungs of the host via FHA and FIM, multiply locally, and release
toxins (Kilgore et al., 2016). Then, the produced toxins cause inflammation, paralyze the cilia, and
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interfere with the evacuation of pulmonary secretions (Figure 2) (CDC, 2020d). Thus, this cascade
of events translates into pertussis clinical features.

Figure 2. Pathogenesis of B. pertussis infection.
Source: Carbonetti, 2007.
3. Clinical features
The clinical course of pertussis is divided into three stages. First, the catarrhal stage (1–2 weeks)
is characterized by an insidious onset of cold-like symptoms such as nasal congestion, sneezing,
mild cough, and a low-grade fever. During the paroxysmal stage (1–6 weeks), the symptoms
persist and become more severe (Figure 3). The patient experiences uninterrupted bursts of
cough, called paroxysms, due to the difficulty of expelling thick mucus through the swollen
airways and followed by a long inspiratory phase characterized by the whooping sound (Mattoo
& Cherry, 2005). Complications include vomiting, collapsed lungs, rib fractures, and petechiae as
capillaries burst due to the pressure. This stage can manifest with gasping, cyanosis, apnea, and
apparent life-threatening events in small infants. The decreased oxygen levels can cause seizures,
encephalopathy, and death (Heininger, 2019). The transition to the convalescent stage is gradual
5

and marked by a decrease in the paroxysms' frequency and severity. Though, it can last up to 6
weeks (Kilgore et al., 2016). Adolescents, adults, and children previously immunized against
pertussis through vaccination or natural infection usually have milder symptoms, but they can
still infect susceptible persons with no or incomplete immunity (CDC, 2020d). Infants younger
than 12 months of age are at higher risks for severe outcomes (Table 1) (Kilgore et al., 2016).

Figure 3. Clinical course of pertussis infection.
Source: https://www.cdc.gov/pertussis/clinical/features.html.
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Table 1. Clinical complications of pertussis among infants, adolescents, and adults from 1981 –
2015.
Source: (Kilgore et al., 2016)
Frequencies (%) in:
Clinical complications

Infants

Adolescents and adults

~ 50

0 – 12

Apnea

50 – 67

27 – 86

Pneumonia

20 – 23

0.6 – 8

Convulsions

1

0 – 0.6

1 – 1.6

0.01

Insomnia

-a

77

Sinusitis

-

13

Otitis media

6

4

Weight loss

12

3 – 33

Urinary incontinence

-

3 – 28

Syncope

-

2–6

Rib fracture

-

1–4

Loss of consciousness

-

1

Hospitalization

Death

a

data not available

4. Transmission
Pertussis is transmitted from person to person through airborne droplets when an infected
person coughs, sneezes, or share breathing space with susceptible individuals. Susceptible
individuals are unvaccinated infants, immunocompromised people, pregnant women, and the
elderly. It is considered highly contagious, far more than polio, smallpox, rubella, mumps, and
diphtheria (Kilgore et al., 2016). Pertussis reproduction number (R0) was estimated to be 5.5, but
studies have shown that one infected person can transmit B. pertussis to as many as 12 – 17 other
susceptible individuals (Kretzschmar et al., 2010).
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5. Diagnosis
Pertussis can be diagnosed clinically, as well as with laboratory testing. The specimen is usually
collected with a nasopharyngeal swab from all suspected cases (CDC, 2021c). Culture is the gold
standard laboratory test. It is highly specific when performed during the first 2 weeks of cough
onset (CDC, 2020d). The PCR became widely used in the last 20 years because it is rapid and has
a higher sensitivity than conventional culture (CSTE, 2019). It provides accurate results for up to
4 weeks of cough in infants or unvaccinated persons. Moreover, PCR assay protocols can also
differentiate B. pertussis from other Bordetella species (CDC, 2020d). Serology is more useful in
the later stage of the disease when both culture and PCR can no longer detect infection (CSTE,
2019). It may be performed on a specimen collected up to 12 weeks following cough onset (CDC,
2020d).
6. Treatment and prevention
Macrolides antibiotics (e.g., erythromycin, clarithromycin, or azithromycin) were proven to be
effective against B. pertussis infection (Kilgore et al., 2016). In addition, antibiotics may reduce
the duration of the infectious period. Close contacts of infected individuals are also
recommended to get postexposure prophylaxis (PEP) administration. However, the rise of
antibiotic resistance in recent years may have impacted the management of pertussis cases
(Kilgore et al., 2016). Vaccination remains a global prevention strategy. In the U.S., a whole-cell
vaccine was introduced in the 1940s and abandoned 30 years later due to several reported
adverse events (Chiappini et al., 2013). Subsequently, acellular vaccines were demonstrated to
be effective and have been routinely used since the 1990s. However, they only protect about 4
– 7 years, whereas whole-cell vaccines can protect up to 5 – 14 years (Kilgore et al., 2016).
Currently, DTaP and Tdap are pertussis-containing vaccines recommended by the CDC (Figure 4).
Children are considered fully vaccinated if they receive 5 doses of DTaP or 4 doses of DTaP if the
fourth dose was administered on or after the fourth birthday (CDC, 2020a).
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Figure 4. Recommended pertussis vaccination calendar.
Adapted from the CDC (https://www.cdc.gov/vaccines/vpd/pertussis/index.html).
7. Surveillance case definition and classification
Pertussis CD has been updated three times from 2010 – 2020. In 2010, the case classification was
reformatted to clarify the wording, but no substantive change was made to the CD used since
1997 (Table 2).
Table 2. Pertussis classification based on the 2010 CSTE/CDC case definition.
Adapted from the NNDSS (https://ndc.services.cdc.gov/case-definitions/pertussis-2010/).
Criteria

Probable case

Confirmed case

Cough duration

≥ 2 weeks

Any

≥ 2 weeks

≥ 2 weeks

Clinical criteriaa

At least one of the

-

At least one

At least one

symptom

symptom

symptoms
Laboratory

Absence

Culture +

PCR +

-

No

-

-

Yes

confirmation
Epidemiologic
linkage to a
laboratoryconfirmed case
a

Clinical criteria include paroxysms or inspiratory whoop or post-tussive vomiting

In 2014, the CSTE intended to accurately capture the burden of disease in infants < 1 year by
including apnea as a defining accessory symptom and removing the requirement for coughs ≥ 2
weeks for this age group (Table 3).
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Table 3. Pertussis classification based on the 2014 CSTE/CDC case definition.
Adapted from the NNDSS (https://ndc.services.cdc.gov/case-definitions/pertussis-2014/).
Criteria

Probable

Probable case for infants < 1 year

Confirmed case

case
Cough

≥ 2 weeks

Any

Any

Any

≥ 2 weeks

≥ 2 weeks

At least one

At least one of

At least one of

-

At least one

At least one

of the

the symptoms

the symptoms

of the

of the

symptoms

symptoms

duration
Clinical
criteria

a

symptoms
Laboratory

Absence

PCR +

-

Culture +

PCR +

-

No

-

Yes

-

-

Yes

confirmation
Epidemiologic
linkage to a
laboratoryconfirmed
case
aClinical

criteria include paroxysms or inspiratory whoop or post-tussive vomiting or apnea ± cyanosis (for infants < 1 year only)

In 2020, the CSTE updated the 2014 CSTE/CDC case definition by classifying PCR-positive cases as
confirmed, regardless of cough duration and presence of pertussis symptoms. Its application
limits the confirmed cases to those with laboratory confirmation and removes the age-specific
classification (CSTE, 2019) (Table 4).
Table 4. Pertussis classification based on the 2020 CSTE/CDC case definition.
Adapted from the NNDSS (https://ndc.services.cdc.gov/case-definitions/pertussis-2020/).
Criteria

Probable case

Confirmed case

Cough duration

Any

Any

Clinical criteriaa

At least one of the symptoms

-

-

Culture + or PCR +

Yes

-

Laboratory confirmation
Epidemiologic linkage to a
laboratory-confirmed case
a

Clinical criteria include paroxysms or inspiratory whoop or post-tussive vomiting or apnea ± cyanosis
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8. Research question
The present study aims to answer whether the application of the new pertussis CD captures more
pertussis cases than the previous CDs. Thus, this study assesses whether the number of
confirmed and probable pertussis cases reported in Georgia from 2010-2020 increases using the
2020 CSTE/CDC case definition and measures whether the new CD is a more effective surveillance
tool than the previous pertussis CDs.

11

Chapter III – Materials and Methods
1. Ethical consideration
The present study was approved by the Internal Review Board of Georgia State University (GSU)
and the Georgia Department of Public Health (DPH). The use of secondary data put it under the
exempt category. Deidentified data was requested from DPH through the Public Health
Information Portal (PHIP).
2. Data collection
The population data were obtained from the publicly available Online Analytical Statistical
Information System (OASIS). Georgia population counts from 2010 to 2020 for all ages, genders,
races and ethnicities were extracted by year. Epidemiologic data were obtained from the State
Electronic Notifiable Disease Surveillance System (SendSS). Pertussis cases are electronically
transmitted to SendSS after a verbal report has been made to the local health department or a
filing of a Pertussis Report Form by the districts, forwarded to the Epidemiology Branch.
Pertussis-related variables included in patient demographics, signs and symptoms, complications
and other symptoms, treatment, laboratory tests, vaccination history, epidemiologic
information, patient setting, and maternal TdaP information for mothers of infants < 1 year were
used in the analysis.
3. Data cleaning
The SAS 9.4 package was used to re-evaluate the reported pertussis cases as confirmed, probable,
and not-a-case (NAC), based on the 2020 CSTE/CDC case definition. The NAC included the
deleted, not confirmed, out-of-state, pending cases, and cases from unknown counties.
Duplicated data entries were filtered by the unique identifier assigned by state (STATECASEID)
and date of onset (DOO) variables, then deleted. The old CD corresponds to the 2010 CSTE/CDC
definition for cases reported between 2010 – 2013 and the 2014 CSTE/CDC definition for cases
reported between 2014 – 2019. On the other hand, the new CD corresponds to the 2020
CSTE/CDC case definition. Next, dichotomous variables were created for the new CD's clinical,
laboratory, and epidemiologic criteria. Then, pertussis cases were reclassified as confirmed,

12

probable, or NAC. Confirmed and probable cases that met the necessary criteria were grouped
as cases, whereas those that did not meet the criteria were NACs.
4. Data analysis
A cross-sectional study was performed. First, the characteristics of all pertussis cases reported
from 2010 to 2020 were described. Next, pertussis cases reported during the 2010 – 2013 and
2014 – 2019 periods were compared with the reclassified ones. As the new CD was already used
for pertussis cases reported during 2020, these cases were reclassified using the 2014 CSTE/CDC
definition, and the differences were calculated. Then, the incidence rates (per 100,000 personyears) of the cases and NACs were compared under the old and new CDs. The sensitivity,
specificity, predictive value positive (PVP), and predictive value negative (PVN) were estimated
by testing the new CD against the old CD with a two-by-two table. These measures were
calculated using the formulas below.
𝑇𝑟𝑢𝑒 𝑝𝑒𝑟𝑡𝑢𝑠𝑠𝑖𝑠 𝑐𝑎𝑠𝑒𝑠

Sensitivity = 𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑 𝑎𝑠 𝑝𝑒𝑟𝑡𝑢𝑠𝑠𝑖𝑠 𝑐𝑎𝑠𝑒𝑠
Specificity =

𝑇𝑟𝑢𝑒 𝑛𝑜𝑛−𝑝𝑒𝑟𝑡𝑢𝑠𝑠𝑖𝑠 𝑐𝑎𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑝𝑜𝑟𝑡𝑒𝑑 𝑎𝑠 𝑛𝑜𝑛−𝑝𝑒𝑟𝑡𝑢𝑠𝑠𝑖𝑠 𝑐𝑎𝑠𝑒𝑠
𝑇𝑟𝑢𝑒 𝑝𝑒𝑟𝑡𝑢𝑠𝑠𝑖𝑠 𝑐𝑎𝑠𝑒𝑠

PVP = 𝑇𝑜𝑡𝑎𝑙 𝑐𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑒𝑑 𝑎𝑠 𝑝𝑒𝑟𝑡𝑢𝑠𝑠𝑖𝑠 𝑐𝑎𝑠𝑒𝑠
𝑇𝑟𝑢𝑒 𝑛𝑜𝑛−𝑝𝑒𝑟𝑡𝑢𝑠𝑠𝑖𝑠 𝑐𝑎𝑠𝑒𝑠

PVN = 𝑇𝑜𝑡𝑎𝑙 𝑐𝑙𝑎𝑠𝑠𝑖𝑓𝑖𝑒𝑑 𝑎𝑠 𝑛𝑜𝑛−𝑝𝑒𝑟𝑡𝑢𝑠𝑠𝑖𝑠 𝑐𝑎𝑠𝑒𝑠
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Chapter IV – Results
There were 3,882 pertussis cases reported in Georgia from 2010 to 2020. Fifty two percent
(n=2,032) were confirmed cases, 22.41% (n=870) probable cases, and 25.24% (n=980) NAC. The
incidence of pertussis cases was higher in 2014 than in other years, with 60% (n=332) confirmed
cases.

Pertussis cases reported by year
350

Number of cases

300
250
200
Confirmed
150

Probable

100

Not-a-case

50
0
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Year

Figure 5. Trends of pertussis cases in Georgia from 2010 – 2020.
1. Characteristics of reported pertussis cases
Description of the population
About 22% (n=867) of reported pertussis cases were among infants < 1 year. More than half
(n=2,217) of the pertussis cases were reported in females, and 69% in NH Whites. The
characteristics of the overall pertussis cases are summarized in Table 5.
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Table 5. Demographic characteristics of pertussis cases in Georgia from 2010-2020 (N=3,882).
Frequency (n)

Percent (%)

Incidence per 100,000
person-years

<1

867

22.37

60.42

1-9

1,082

27.92

7.99

10-19

785

20.25

5.01

20-29

134

3.46

0.84

30-39

201

5.19

1.32

40-49

249

6.42

1.62

50-59

213

5.50

1.45

60-69

191

4.93

1.70

70-79

116

2.99

1.87

80+

38

0.98

1.22

Female

2,217

57.11

3.85

Male

1,662

42.81

3.04

NHa White

2,493

64.22

4.43

NH Black

608

15.66

1.75

Hispanic

438

11.28

0.59

NH Asian

62

1.60

0.14

Otherb

281

7.24

4.00

Age category (years)

Gender

Race/Ethnicity

a
b

NH: Non-Hispanic
Other includes Natives, multiracial and unknown race

Signs and symptoms
All reported case-patients presented a cough onset (N=3,882). The clinical characteristics of
these cases are summarized in Table 6.
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Table 6. Clinical characteristics by case classification of pertussis cases in Georgia from 2010-2020
(N=3,882).
Confirmed cases

Probable cases

NACsa

(n=2,032)

(n=870)

(n=980)

n (%)

n (%)

n (%)

2,032 (100)

870 (100)

980 (100)

< 14 days

22 (1.09)

17 (1.97)

204 (26.60)

≥ 14 days

1,987 (98.17)

833 (96.30)

381 (49.67)

Paroxysms

1,893 (93.25)

795 (91.48)

248 (25.97)

751 (37.10)

283 (32.60)

71 (7.47)

1,177 (58.01)

381 (43.79)

130 (13.60)

Apnea

361 (18.63)

54 (6.43)

33 (3.71)

Cyanosis

322 (16.86)

35 (4.24)

24 (2.64)

Fever

167 (17.47)

120 (21.13)

113 (19.19)

n (%)

n (%)

n (%)

Pneumonia

63 (10.90)

62 (16.45)

39 (16.88)

Seizure

16 (0.79)

3 (0.35)

2 (0.21)

Encephalopathy

8 (0.40)

6 (0.69)

3 (0.32)

397 (19.54)

61 (7.01)

74 (7.55)

1 (0.05)

2 (0.24)

5 (0.52)

Signs and symptoms
Cough
Cough duration

Whoop
Post-tussive vomiting

Complications

Hospitalized
Died
a

NACs: Not-a-cases

Laboratory evidence
Ninety-two percent (n=3,560) of the reported pertussis cases had laboratory testing done. PCR
was ordered in 62.28% (n=2,176), whereas culture in 8.67% (n=303) only. More than 50% of the
laboratory-confirmed cases were obtained from PCR (Table 7).
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Table 7. Proportions of laboratory-confirmed pertussis cases in Georgia from 2010 – 2020.

a

PCR n (%)

Culture n (%)

Othera n (%)

Positive n (%)

1,795 (51.37)

85 (2.43)

928 (26.56)

Negative n (%)

294 (8.41)

100 (2.86)

63 (1.8)

Other includes DFA, IgA, IgG, IgM, serology, panel, and unknown tests.

Epidemiology
None of the case-patients reported were previously diagnosed with pertussis. Fifty-nine percent
(n=1,455) were completely vaccinated, whereas 39.24% (n=965) were incompletely vaccinated
and 1.59% (n=39) were unvaccinated. The vaccination history by case classification is summarized
in Table 8. Thirty-six percent (n=1,423) of the vaccination status variable were missing values.
The main reasons for being unvaccinated were: too young (n=445, 32.74%), unknown (n=423,
31.13%), parent/patient refusal (n=190, 13.98%). About 7% (n=275) cases were associated with
a known pertussis outbreak, and 21.22% (n=807) were epidemiologically linked to a laboratoryconfirmed case. Five percent (n=198) were employed at or attended a daycare facility, 31.60%
(n=879) were at school. The transmission setting was unknown (n=2,316, 65.02%) most of the
time, then at home (n=793, 22.26%) and school (n=187, 5.25%). About 78% (n=2,174) of the casepatients reported they did not spread pertussis outside their household. For infant cases, the
source of infection identified was more likely from the elderly (68.09%, n=256), children 1 – 9
years (13.30%, n=50), and adolescents 10 – 19 years (6.38%, n=24). Transmission from young
adults (20 – 29 years) and adults (30 – 39 years) to infants < 1 year were found in 5.05% (n=19)
and 4.26% (n=16), respectively. The mother was the source of infection in 6.99% (n=29) cases.
Table 8. Vaccination history of pertussis case-patients in Georgia from 2010 – 2020 (N=2,459).
Confirmed cases n (%)

Probable cases n (%)

NACs n (%)

Completely vaccinated

779 (31.68)

356 (14.48)

320 (13.01)

Incompletely vaccinated

584 (23.75)

164 (6.67)

217 (8.82)

30 (1.22)

4 (0.16)

5 (0.20)

Unvaccinated

17

Maternal TDAP Information - only for mothers of case-patients < 1 year
About 64% (n=464) of mothers have ever received the Tdap vaccine. Sixteen percent (n=117)
were vaccinated during pregnancy, and 20.96% (n=96) received the shot during their third
trimester. Among the 54.37% (n=249) unvaccinated mothers during pregnancy, the reason for
not being vaccinated was unknown in 25.74% (n=140) cases, whereas 23.16% (n=126) did not
recall being vaccinated, 21.51% (n=117) got vaccinated after pregnancy, and 10.66% (n=58)
declined vaccination.
2. Variability of pertussis incidence using case definitions
From 2010 to 2019, 916 (25.12%) reported cases were classified as NACs. About nine percent
(n=311) of these cases were reclassified as cases after using the new CD. Two CDs were used
during that period.
First, between 2010 and 2013, 216 (17.79%) reported cases were classified as NACs using the
2010 CSTE/CDC case definition. Seven percent (n=85, 95% CI: [4.23% – 9.77%]) of these cases
were reclassified as cases, either confirmed or probable, after using the 2020 CSTE/CDC case
definition. This comparison is shown in Table 9.
Table 9. Pertussis case classification in Georgia from 2010 – 2013 (N=1,214).
2010 CDa n (%)

2020 CD n (%)

Difference n (%) =
2020 CD – 2010 CD

95% CIb [%]

Casec

998 (82.21)

1083 (89.21)

-85 (-7.00)

[-9.77 – -4.23]

NACd

216 (17.79)

131 (10.79)

85 (7.00)

[4.23 – 9.77]

a

CD: Case definition
CI: Confidence interval
c
Case includes confirmed and probable
d
NAC: Not-a-case
b

Then, between 2014 and 2019, 700 (28.78%) reported cases were classified as NACs using the
2014 CSTE/CDC case definition. Nine percent (n=226, 95% CI: [6.90% – 11.68%]) of these cases
were reclassified as cases, either confirmed or probable, after using the 2020 CSTE/CDC case
definition. This comparison is shown in Table 10.
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Table 10. Pertussis case classification in Georgia from 2014-2019 (N=2,432).
2014 CDa n (%)

2020 CD n (%)

Difference n (%) =
2020 CD – 2014 CD

95% CIb [%]

Casec

1,732 (71.22)

1,958 (80.51)

-226 (-9.29)

[-11.68 – -6.90]

NACd

700 (28.78)

474 (19.49)

226 (9.29)

[6.90 – 11.68]

a

CD: Case definition
CI: Confidence interval
c
Case includes confirmed and probable
d
NAC: Not-a-case
b

In 2020, the new CD classified 96 (40.68%) reported cases as confirmed, 76 (32.20%) as probable,
and 64 (27.12%) as NACs. Fifty-eight percent (n=137, 95% CI: [50.79% – 65.31%]) of these cases
would have been missed if the 2014 CSTE/CDC case definition was still in use. This comparison is
shown in Table 11.
Table 11. Reclassification of the 2020 pertussis cases using the 2014 CD (N=236).
2020 CDa n (%)

2014 CD n (%)

Difference n (%) =
2020 CD – 2014

95% CIb [%]

Casec

172 (72.88)

35 (14.83)

137 (58.05)

[50.79 – 65.31]

NACd

64 (27.12)

201 (85.17)

-137 (-58.05)

[-65.31 – -50.79]

a

CD: Case definition
CI: Confidence interval
c
Case includes confirmed and probable
d
NAC: Not-a-case
b

Overall, between 2010 and 2020, 2,765 (71.23%) reported cases were considered as pertussis
cases (confirmed and probable), and 1,117 (28.77%) were NACs, using the 2010 CSTE/CDC case
definition from 2010 – 2013, and the 2014 CSTE/CDC case definition from 2014 – 2019. After
reclassification based on the 2020 CSTE/CDC case definition, 3,213 (82.77%) were considered as
cases, whereas 669 (17.23%) were NACs (Figure 6). There were 448 (11.54%, 95% CI: [9.69% –
13.40%]) cases captured with the new CD.
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Figure 6. Pertussis incidence in Georgia from 2010 – 2020 using the old and new case definitions.
The incidence rates of these pertussis cases calculated from the total population (N=
112,338,777) in Georgia from 2010 – 2020 are shown in Table 12.
Table 12. Incidence rates of pertussis cases in Georgia from 2010 – 2020 based on case definitions
(N= 112,338,777).
Old CDa

New CD

Caseb (per 100,000 person years)

2.46

2.86

NACc (per 100,000 person-years)

0.99

0.60

Incidence rate

a

CD: Case Definition
Case includes confirmed and probable
c
NAC: Not-a-case
b

3. Assessment of the 2020 CSTE/CDC case definition
In the two-by-two table below (Table 13), 448 is hypothetically false negative or false nonpertussis cases. By deducting it from the total reported as pertussis cases under the old CD, 2,317
would be true positive or true pertussis cases. In the same way, subtracting the false negative
from the total reclassified as non-pertussis cases under the new CD would give 221 true negative
or true non-pertussis cases. Consequently, 896 would be false positive or false pertussis cases.
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Table 13. Two-by-two table comparing the old CD and the new CD.
Old CDa

New CD

Case (n)

NAC (n)

Total

Caseb (n)

2,317

896

3,213

NACc (n)

448

221

669

Total

2,765

1,117

3,882

a

CD: Case Definition
Case includes confirmed and probable
c
NAC: Not-a-case
b

As a result, the new CD has an estimated sensitivity of 83.80% (±0.70%, 95% CI: [82.42% –
85.17%]), a specificity of 19.79% (±1.19%, 95% CI: [17.45% – 22.12%]), a predictive value positive
of 72.11% (±0.79%, 95% CI: [70.56% – 73.66%]), and a predictive value negative of 33.03%
(±1.82%, 95% CI: [29.47% – 736.60%]) (Table 14).
Table 14. Measures of validity of the new pertussis case definition.
Measures

Estimate %

Standard Error %

95% CIa %

Sensitivity

83.80

0.70

[82.42 – 85.17]

Specificity

19.79

1.19

[17.45 – 22.12]

PVPb

72.11

0.79

[70.56 – 73.66]

PVNc

33.03

1.82

[29.47 – 36.60]

a

CI: confidence interval
PVP: predictive value positive
c
PVN: predictive value negative
b
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Chapter V – Discussion and Conclusions
Pertussis is a remerging infectious disease that needs better control and surveillance.
Our findings show that reported pertussis cases were high in Georgia in 2014. It could be related
to the application of the 2014 CSTE/CDC case definition that addressed the significant numbers
of infant cases with positive PCR results but not meeting the required clinical criteria. A previous
study conducted at the Georgia Department of Public Health (DPH) reported an 11.4% increase
in the number of infant cases between 2010 and 2013, using this 2014 CSTE/CDC case definition
(Thomas & Tuttle, 2016).
The results show no differences in pertussis incidence across gender and race/ethnicity.
However, the disease burden is higher among infants < 1 year, consistent with other studies
(Gabutti et al., 2015). In the U.K., the highest pertussis mortality rate occurred in this age group
(Billingsley, 2012). More precisely, children under 6 months of age have been reported to present
severe and life-threatening disease manifestations (Arehart et al., 2019).
The clinical characteristics pointed out that cough is a constant sign observed in all reported
cases. Usually, the cough worsens in both frequency and degree over a 7- to 14-day period
(Mattoo & Cherry, 2005). The proportion of patients having a cough duration < 14 days or ≥ 14
days is almost the same between confirmed and probable cases, but nearly half of the NACs had
a cough more than 14 days. So, cough duration was inconsistent across case classification.
Similarly, the other signs and symptoms were not significantly different between confirmed and
probable cases, and they were irregular for NACs.
Regarding the complications, hospitalization was 3 times higher among confirmed than probable
cases. However, fewer pertussis-related deaths (0.29%) were reported in Georgia between 2010
and 2020 compared to 58% of estimated deaths in the African region (Yeung et al., 2017). The
WHO reported an average range of pertussis mortality rates between 3 and 10 per 1 million births
in high-income countries from 2003 – 2012 (Chow et al., 2016).
The present study shows a greater proportion of laboratory-confirmed pertussis cases obtained
from PCR than culture or other laboratory tests. Indeed, it aligns with the CSTE's objective to rely
on a frequently used diagnostic tool than the inconsistent duration of cough. Although culture is
more specific than PCR, it is only sensitive at 60% if the samples are collected within the first 2 –
22

3 weeks after cough onset (WHO, 2014). Serology was among the earliest confirmation diagnostic
tools of pertussis, but previous vaccinations or infections, cross-reactivity with other Bordetella
species, and variable response to B. pertussis antigens can interfere with the serodiagnosis (van
der Zee et al., 2015). Nevertheless, it was found that positivity with serological diagnosis (IgA and
IgG titers) improved with increasing age and duration of disease (van der Zee et al., 1996).
The missing values in the vaccination status variable did not allow a comprehensive vaccination
history by age group. However, children aged 7 – 10 years are considered susceptible to waning
immunity despite having completed the DTaP vaccination series because they would have not
yet received the Tdap booster recommended at age 11 – 12 years (Winter et al., 2012). Also,
being too young was the most frequent (32.74%) reason for not being fully vaccinated against
pertussis, as mentioned in other publications (Chow et al., 2016).
Usually, young infants contract pertussis from their mothers, but we found the source of infection
was more likely from the elderly (68.09%, n=256), older children (13.30%, n=50), and adolescents
(6.38%, n=24). In cases where the mothers were the source of infection, the onset of symptoms
occurred in the pregnant women before delivery (de Greeff S. C. et al., 2010). Thus, vaccination
of mothers during pregnancy or post-partum has been adopted as a prevention method. Also,
the cocooning strategy that consists of vaccinating individuals in close contact with infants too
young to receive the vaccine is recommended (Althouse & Scarpino, 2015).
In 2020, we noticed that pertussis incidence in Georgia was lower compared to that of previous
years. The COVID-19 pandemic might have impacted the reporting of notifiable diseases in
general during that time. Still, fifty-eight percent (n=137) of pertussis cases would have been
missed in 2020 if the 2014 CSTE/CDC case definition was still in use. The incidence rate of
pertussis cases was 1.16 times higher with the new CD than the old CD. Thus, specifying
appropriate case definitions is essential in emerging infectious diseases to identify cases
efficiently and limit their spread (Gregg, 2003). Yet, evaluating pertussis incidence is complicated
due to the nonuniformity of case definitions across different surveillance systems (Kilgore et al.,
2016). During the SARS outbreak in 2003, for example, a centralized assessment of reported cases
by a team with clinical and public health expertise was a practical solution for addressing
differences in applying case definitions (Timen et al., 2006).
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Sensitivity is an essential characteristic of a case definition. It is the capacity of a surveillance
system to ascertain the health problem that it is intended to detect (CDC, 2020c). Likewise,
predictive value positive (PVP) is the proportion of reported or identified cases that are truly
cases (CDC, 2020c). A high PVP is preferred because it permits the allocation of appropriate
surveillance resources; false-positive reports may lead to unnecessary investigations and
unwarranted concerns in the community (Klaucke et al., 2001). Thus, the present study suggests
that the 2020 CSTE/CDC case definition detects pertussis cases at 83.80%, and the identified
cases are truly cases at 72.11%.
Limitations
Although the application of the new CD seems to improve the surveillance of pertussis in our
analysis, this study has encountered several limitations.
Concerning the burden of pertussis, it was not possible to specify the age of infants < 1 year by
months to have a more granular analysis, as seen in other studies. For instance, Masseria et al.
reported an overall pertussis incidence rate of 117.7 per 100,000 person-years among infants <
12 months, and the highest incidence rate (247.7/100,000 person-years) was found among 3month-olds (Masseria et al., 2017).
Also, it was challenging to establish whether the pertussis vaccines received by case-patients
were coherent with the recommended calendar. The de-identified data did not contain the date
of birth variable to calculate age at vaccination. Thus, those who received 5 doses of pertussiscontaining vaccine prior to illness onset were considered fully vaccinated in this analysis,
regardless of age-appropriateness.
Next, the responses to pertussis spread outside the household during case investigations may be
subject to social desirability bias as individuals would report they remained home during their
infectious period. Reporting bias could also apply to the reasons for not being vaccinated.
Further, the patient setting variables' low rate of completeness report might have overestimated
the epidemiologic linkage of pertussis cases, resulting in more probable cases. Last, the estimated
sensitivity of the new CD was limited to the case reporting level, but its ability to detect epidemics
has not been evaluated. Validity measures of previous pertussis CDs were not available to
compare with those of the new CD; the outcomes only indicate that it is more sensitive than
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specific and has a better PVP than PVN. Although our results may not be generalizable across the
U.S., they can still be used as benchmarks for future research.

In conclusion, pertussis remains a public health issue with a high burden among infants < 1 year.
Changing the clinical criteria of illness of cough ≥ 2 weeks to cough of any duration, and
accounting PCR-positive cases as laboratory-confirmed cases were found to be effective in
capturing more pertussis cases in Georgia. Despite the limitations of this study, it demonstrates
the usefulness of updating case definitions with reliable diagnostic tools. These findings can be
used to reinforce the capacity of health districts and public health departments to identify
pertussis cases accurately and deploy the necessary resources. Standardized and evidence-based
tools are essential for notifiable diseases surveillance to monitor trends and stop epidemics on
time. Future research could expand on adopting an integrated approach to surveillance of
emerging infectious diseases.
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